Advertisement
Letter to the Editor| Volume 166, P33-37, May 2022

Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction

Published:March 08, 2022DOI:https://doi.org/10.1016/j.ejca.2022.01.026
Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction
Previous ArticleEvaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors
Next ArticleInadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla™ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib
      Medication-related osteonecrosis of the jaw (ONJ) is an adverse event (AE) of antiresorptive treatments, firstly reported with the use of bisphosphonates. It is defined as an area of exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region, that persisted for more than eight weeks in patients exposed to these drugs [
      • Ruggiero S.L.
      • Dodson T.B.
      • Fantasia J.
      • Goodday R.
      • Aghaloo T.
      • Mehrotra B.
      • et al.
      American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update.
      J Oral Maxillofac Surg. 2014; 72: 1938-1956https://doi.org/10.1016/j.joms.2014.04.031
      ]. The pathophysiology is multifactorial, being correlated with the dose and duration of exposure to antiresorptive drugs as well as the type, pre-existing dental disease, poor oral hygiene, and oral surgery immediately preceding or during treatment with antiresorptive agents [
      • Khan A.A.
      • Morrison A.
      • Hanley D.A.
      • Felsenberg D.
      • McCauley L.K.
      • O'Ryan F.
      • et al.
      Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
      J Bone Miner Res. 2015; 30: 3-23https://doi.org/10.1002/jbmr.2405
      ,
      • Anastasilakis A.D.
      • Pepe J.
      • Napoli N.
      • Palermo A.
      • Magopoulos C.
      • Khan A.A.
      • et al.
      Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by ECTS.
      J Clin Endocrinol Metabol. 2021; dgab888https://doi.org/10.1210/clinem/dgab888
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Ruggiero S.L.
        • Dodson T.B.
        • Fantasia J.
        • Goodday R.
        • Aghaloo T.
        • Mehrotra B.
        • et al.
        American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update.
        J Oral Maxillofac Surg. 2014; 72: 1938-1956https://doi.org/10.1016/j.joms.2014.04.031
        View in Article
        • Khan A.A.
        • Morrison A.
        • Hanley D.A.
        • Felsenberg D.
        • McCauley L.K.
        • O'Ryan F.
        • et al.
        Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
        J Bone Miner Res. 2015; 30: 3-23https://doi.org/10.1002/jbmr.2405
        View in Article
        • Anastasilakis A.D.
        • Pepe J.
        • Napoli N.
        • Palermo A.
        • Magopoulos C.
        • Khan A.A.
        • et al.
        Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by ECTS.
        J Clin Endocrinol Metabol. 2021; dgab888https://doi.org/10.1210/clinem/dgab888
        View in Article
        • Baba A.
        • Goto T.K.
        • Ojiri H.
        • Takagiwa M.
        • Hiraga C.
        • Okamura M.
        • et al.
        CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaws.
        Dentomaxillofacial Radiol. 2018; : 20170323https://doi.org/10.1259/dmfr.20170323
        View in Article
        • Boquete-Castro A.
        • Gómez-Moreno G.
        • Calvo-Guirado J.L.
        • Aguilar-Salvatierra A.
        • Delgado-Ruiz R.A.
        Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.
        Clin Oral Implants Res. 2016; 27: 367-375https://doi.org/10.1111/clr.12556
        View in Article
        • Rachner T.D.
        • Platzbecker U.
        • Felsenberg D.
        • Hofbauer L.C.
        Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
        Mayo Clin Proc. 2013; 88: 418-419https://doi.org/10.1016/j.mayocp.2013.01.002
        View in Article
        • Kyrgidis A.
        • Toulis K.A.
        Denosumab-related osteonecrosis of the jaws.
        Osteoporos Int. 2011; 22: 369-370https://doi.org/10.1007/s00198-010-1177-6
        View in Article
        • Heim N.
        • Götz W.
        • Kramer F.-J.
        • Faron A.
        Antiresorptive drug-related changes of the mandibular bone density in medication-related osteonecrosis of the jaw patients.
        Dentomaxillofacial Radiol. 2019; 48: 20190132https://doi.org/10.1259/dmfr.20190132
        View in Article
        • Pichardo S.E.C.
        • Broek F.W.T.
        • Fiocco M.
        • Appelman-Dijkstra N.M.
        • van Merkesteyn J.P.R.
        A comparison of the cone beam computed tomography findings in medication-related osteonecrosis of the jaws related to denosumab versus bisphosphonates: an observational pilot study.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2020; 129: 411-417https://doi.org/10.1016/j.oooo.2019.09.010
        View in Article
        • Klingelhöffer C.
        • Klingelhöffer M.
        • Müller S.
        • Ettl T.
        • Wahlmann U.
        Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw?.
        Dentomaxillofacial Radiol. 2016; 45: 20160065https://doi.org/10.1259/dmfr.20160065
        View in Article
        • Querrer R.
        • Ferrare N.
        • Melo N.
        • Stefani C.M.
        • dos Reis P.E.D.
        • Mesquita C.R.M.
        • et al.
        Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review.
        Support Care Cancer. 2021; 29: 2811-2820https://doi.org/10.1007/s00520-020-05855-6
        View in Article
        • Vilarinho J.L.P.
        • Ferrare N.
        • Moreira A.M.R.
        • Moura H.F.
        • Acevedo A.C.
        • Chaves S.B.
        • et al.
        Early bony changes associated with bisphosphonate-related osteonecrosis of the jaws in rats: a longitudinal in vivo study.
        Arch Oral Biol. 2017; 82: 79-85https://doi.org/10.1016/j.archoralbio.2017.06.002
        View in Article
        • Lorenzo-Pouso A.
        • Perez-Sayans M.
        • Gonzalez-Palanca S.
        • Chamorro-Petronacci C.
        • Bagan J.
        • Garcia-Garcia A.
        Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: a systematic review.
        Med Oral. 2018; : 0-0https://doi.org/10.4317/medoral.22763
        View in Article

      Article info

      Publication history

      Published online: March 08, 2022
      Accepted: January 12, 2022
      Received in revised form: January 4, 2022
      Received: December 10, 2021

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2022.01.026

      Copyright

      © 2022 Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX